Log in

NASDAQ:VTGN - Vistagen Therapeutics Stock Price, Forecast & News

-0.09 (-15.00 %)
(As of 02/28/2020 04:29 AM ET)
Today's Range
Now: $0.51
50-Day Range
MA: $0.71
52-Week Range
Now: $0.51
Volume596,571 shs
Average Volume327,444 shs
Market Capitalization$24.46 million
P/E RatioN/A
Dividend YieldN/A
VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder. It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform to discover, rescue, develop, and commercialize new chemical entities (NCEs) for CNS and other diseases; and regenerative medicine involving hPSC-derived blood, cartilage, heart, and liver cells. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:VTGN



Sales & Book Value

Annual Sales$1.25 million
Book Value($0.13) per share


Net Income$-24,590,000.00


Market Cap$24.46 million
Next Earnings Date6/23/2020 (Estimated)
OptionableNot Optionable

Receive VTGN News and Ratings via Email

Sign-up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter.

Vistagen Therapeutics (NASDAQ:VTGN) Frequently Asked Questions

What is Vistagen Therapeutics' stock symbol?

Vistagen Therapeutics trades on the NASDAQ under the ticker symbol "VTGN."

How were Vistagen Therapeutics' earnings last quarter?

Vistagen Therapeutics Inc (NASDAQ:VTGN) posted its quarterly earnings data on Thursday, February, 13th. The company reported ($0.15) EPS for the quarter, missing the Zacks' consensus estimate of ($0.07) by $0.08. View Vistagen Therapeutics' Earnings History.

When is Vistagen Therapeutics' next earnings date?

Vistagen Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, June 23rd 2020. View Earnings Estimates for Vistagen Therapeutics.

What price target have analysts set for VTGN?

3 analysts have issued 12-month price objectives for Vistagen Therapeutics' stock. Their forecasts range from $0.70 to $4.00. On average, they anticipate Vistagen Therapeutics' stock price to reach $2.35 in the next year. This suggests a possible upside of 360.8% from the stock's current price. View Analyst Price Targets for Vistagen Therapeutics.

What is the consensus analysts' recommendation for Vistagen Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vistagen Therapeutics in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Vistagen Therapeutics.

What are Wall Street analysts saying about Vistagen Therapeutics stock?

Here are some recent quotes from research analysts about Vistagen Therapeutics stock:
  • 1. According to Zacks Investment Research, "VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company's lead product candidate consists of AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder. VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California. " (2/25/2020)
  • 2. Chardan Capital analysts commented, "We transfer coverage of VTGN to better align coverage with current focus areas of analysts. We downgrade to $0.70 price target. We believe that VistaGen Therapeutics now faces an uphill battle after a setback in AV-101 development, one that to us will not be aided by recent pipeline acquisitions. VistaGen announced the NIMH-sponsored phase II trial (NCT02484456) of AV-101 in treatment resistant depression (TRD) missed its primary endpoint of change from baseline on the Scale (HDRS). 19-patient study showed no separation of AV-101 from placebo. The NIMH trial evaluated AV-101 as a monotherapy, whereas VistaGen is positioning AV-101 as an adjunct therapy. However, to us a clinical trial failure does not bode well for the success for AV-101." (7/22/2019)

Has Vistagen Therapeutics been receiving favorable news coverage?

Media headlines about VTGN stock have trended negative on Friday, according to InfoTrie. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Vistagen Therapeutics earned a media sentiment score of -2.7 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Vistagen Therapeutics.

Are investors shorting Vistagen Therapeutics?

Vistagen Therapeutics saw a decrease in short interest in January. As of January 31st, there was short interest totalling 2,640,000 shares, a decrease of 8.3% from the January 15th total of 2,880,000 shares. Based on an average trading volume of 817,900 shares, the days-to-cover ratio is presently 3.2 days. Currently, 7.0% of the shares of the company are sold short. View Vistagen Therapeutics' Current Options Chain.

Who are some of Vistagen Therapeutics' key competitors?

What other stocks do shareholders of Vistagen Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vistagen Therapeutics investors own include Highpower International (HPJ), AK Steel (AKS), Advaxis (ADXS), Rite Aid (RAD), Matinas BioPharma (MTNB), vTv Therapeutics (VTVT), Lithium Americas (LAC), Sorrento Therapeutics (SRNE), Crispr Therapeutics (CRSP) and Yamana Gold (AUY).

Who are Vistagen Therapeutics' key executives?

Vistagen Therapeutics' management team includes the folowing people:
  • Mr. Shawn K. Singh, CEO & Director (Age 56)
  • Dr. H. Ralph Snodgrass, Founder, Pres, Chief Scientific Officer & Director (Age 69)
  • Mr. Jerrold D. Dotson, CFO, VP & Sec. (Age 66)
  • Mr. Mark Adrian McPartland, VP of Corp. Devel. (Age 53)
  • Dr. Mark A. Smith, Chief Medical Officer (Age 64)

Who are Vistagen Therapeutics' major shareholders?

Vistagen Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Geode Capital Management LLC (0.52%) and Blair William & Co. IL (0.12%). Company insiders that own Vistagen Therapeutics stock include H Ralph Snodgrass and Jon S Saxe. View Institutional Ownership Trends for Vistagen Therapeutics.

Which institutional investors are selling Vistagen Therapeutics stock?

VTGN stock was sold by a variety of institutional investors in the last quarter, including Blair William & Co. IL. View Insider Buying and Selling for Vistagen Therapeutics.

Which institutional investors are buying Vistagen Therapeutics stock?

VTGN stock was bought by a variety of institutional investors in the last quarter, including Geode Capital Management LLC. Company insiders that have bought Vistagen Therapeutics stock in the last two years include H Ralph Snodgrass and Jon S Saxe. View Insider Buying and Selling for Vistagen Therapeutics.

How do I buy shares of Vistagen Therapeutics?

Shares of VTGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Vistagen Therapeutics' stock price today?

One share of VTGN stock can currently be purchased for approximately $0.51.

How big of a company is Vistagen Therapeutics?

Vistagen Therapeutics has a market capitalization of $24.46 million and generates $1.25 million in revenue each year. The company earns $-24,590,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis. Vistagen Therapeutics employs 9 workers across the globe.View Additional Information About Vistagen Therapeutics.

What is Vistagen Therapeutics' official website?

The official website for Vistagen Therapeutics is http://www.vistagen.com/.

How can I contact Vistagen Therapeutics?

Vistagen Therapeutics' mailing address is 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-577-3600 or via email at [email protected]

MarketBeat Community Rating for Vistagen Therapeutics (NASDAQ VTGN)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  245 (Thanks for Voting!)
Underperform Votes:  173 (Thanks for Voting!)
Total Votes:  418
MarketBeat's community ratings are surveys of what our community members think about Vistagen Therapeutics and other stocks. Vote "Outperform" if you believe VTGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VTGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/28/2020 by MarketBeat.com Staff

Featured Article: Market Perform

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel